LTS and Revive Therapeutics enter into Feasibility Agreement to develop Oral Psilocybin Thin Film Strip

17.05.2021|Company News|

LTS and Revive Therapeutics Ltd. are pleased to announce that they have entered into a feasibility agreement to develop and manufacture a proprietary oral psilocybin thin film strip for the Company’s clinical and commercial initiatives to evaluate in mental illness, neurological and substance abuse disorders.

LTS and LIVZON enter into license and collaboration agreement to develop and commercialize ASENAPINE TTS

6.07.2020|Press Releases|

LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.

16.12.2019|Company News|

LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.

Go to Top